RESUMO
The following conclusions emerged from an analysis of the therapeutic results documented during the clinical trial of N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino)-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (trimethoprim) (CN 3123, Nevin, Supristol) in bacterial infections of the respiratory tract and ENT organs: 1. In bacterial infections of the bronchopulmonary system, the antibacterial activity of CN 3123 was demonstrated in 94% of the patients, in that 75% of patients were cured and there was a definite improvement in 19%. 2. In bacterial infections of the ENT organs, the antibacterial activity of CN 3123 was demonstrated clinically in 95% of the patients, in that 89% of the patients were cured and there was a definite improvement in 6%. 3. The clinical assessment of the activity of CN 3123 correlates closely with the results of bacteriological checks.
Assuntos
Otorrinolaringopatias/tratamento farmacológico , Infecções Respiratórias/tratamento farmacológico , Sulfamoxol/uso terapêutico , Trimetoprima/uso terapêutico , Doença Aguda , Adolescente , Adulto , Criança , Doença Crônica , Ensaios Clínicos como Assunto , Combinação de Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
The clinical trial of the combination N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (trimethoprim) (CN 3123, Nevin, Supristol) showed that, when given in the ratio of 5:1 and in a suitable dosage computed from pharmacokinetic information, it exhibited antibacterial activity and had a therapeutic effect in about 90% of the patients. In view of the numerous types of pathogen identified in the clinical trial, CN 3123 can be described as a broad-spectrum chemotherapeutic agent. CN 3123 was also effective against infections caused by sulfonamide-resistant or antibiotic-resistant pathogens.
Assuntos
Infecções Bacterianas/tratamento farmacológico , Sulfamoxol/uso terapêutico , Trimetoprima/uso terapêutico , Adolescente , Adulto , Idoso , Antibacterianos/farmacologia , Bactérias/efeitos dos fármacos , Criança , Pré-Escolar , Ensaios Clínicos como Assunto , Combinação de Medicamentos , Avaliação de Medicamentos , Resistência Microbiana a Medicamentos , Feminino , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Sulfonamidas/farmacologiaRESUMO
The antibacterial activity of N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (trimethoprim) (CN 3123, Nevin, Supristol) was studied in various bacterial infections in the fields of internal medicine, dermatology and gynecology. It was found that: 1. CN 3123 exhibits antibacterial activity in bacterial infections of the intestinal tract, particularly in salmonellosis and shigellosis. 2. CN 3123 is effective against bacterial infections of the female genital organs. 3. CN 3123 is very effective in patients with bacterial infections of the skin. 4. The antibacterial activity of CN 3123 in these indications is comparable to its action on bacterial infections of the urinary organs and respiratory tract and in ENT infections.
Assuntos
Gastroenteropatias/tratamento farmacológico , Doença Inflamatória Pélvica/tratamento farmacológico , Dermatopatias Infecciosas/tratamento farmacológico , Sulfamoxol/uso terapêutico , Trimetoprima/uso terapêutico , Adolescente , Adulto , Idoso , Doenças Biliares/tratamento farmacológico , Criança , Ensaios Clínicos como Assunto , Combinação de Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
Two double-blind trials which, independently, revealed the same conclusion that there is no significant difference between the therapeutic effect of N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (trimethoprim) (CN 3123, Neven, Supristol) and a reference preparation, were compared with each other in respect of rating the therapeutic result. The authors discuss the greater occurrence of Proteus pathogens at one trial centre, and its bearing on the rating of the therapeutic effect.
Assuntos
Infecções Bacterianas/tratamento farmacológico , Sulfamoxol/uso terapêutico , Trimetoprima/uso terapêutico , Ensaios Clínicos como Assunto , Combinação de Medicamentos , Humanos , Testes de Sensibilidade Microbiana , Sulfametoxazol/uso terapêuticoRESUMO
1. During the clinical trial of N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (trimethoprim) (CN 3123, Nevin, Supristol) side-effects were reported in only 56 (=4.1%) of the 1371 patients who took part. 2. The numerous laboratory parameters studied in the whole group and in the group which received long-term treatment did not show any significant changes due to CN 3123. 3. The frequency and the type of side-effects which occurred under the combined preparation CN 3123 were the same as those known to be caused by sulfonamide treatment. 4. The good tolerance, which is a familial feature of sulfonamide treatment, is not impaired when sulfamoxole is combined with trimethoprim.
Assuntos
Sulfamoxol/efeitos adversos , Trimetoprima/efeitos adversos , Adolescente , Adulto , Idoso , Glicemia/metabolismo , Criança , Pré-Escolar , Ensaios Clínicos como Assunto , Diabetes Mellitus/sangue , Combinação de Medicamentos , Feminino , Humanos , Lactente , Rim/efeitos dos fármacos , Fígado/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Glândula Tireoide/efeitos dos fármacos , Triglicerídeos/sangueRESUMO
During the clinical trial of N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (trimethoprim) (CN 3123, Nevin, Supristol) results from 925 treated cases of bacterial infections of the urinary organs were documented. The analysis revealed the following conclusions: 1. On the basis of all the assessable cases, there was no clinical effect in less than 10% of patients and no bacteriological effect in only 13% of patients. The therapeutic response was clinically good in 76% and bacteriologically good in 68% of the patients. The rest of the patients showed a fair clinical response, that is to say they showed a definite improvement in the clinical picture, or some bacteriological response, i.e. a definite reduction in the organism counts or, in mixed infections, not all the strains of pathogen were eradicated. 2. There was a higher success rate in acute urinary tract infections which had not previously been treated than in chronic or previously treated cases. 3. The therapeutic results in the principal indications were as follows: Pyelonephritis: 73.9% good and 16.5% fair effect clinically; 63.6% good and 21.6% some effect bacteriologically. Pyelitis: 81.1% good and 18.9% fair effect clinically; 70.4% good and 25.9% some effect bacteriologically. Cystitis: 81.3% good and 8.6% fair effect clinically; 68.9% good and 17.6% some effect bacteriologically. Postoperative urinary tract infections: 98% good effect clinically and bacteriologically. Infections of the urinary organs (not specified in more detail): 71.8% good and 16.1% fair effect clinically; 65.0% good and 18.8% some effect bacteriologically.
